1. Home
  2. RIGL vs UROY Comparison

RIGL vs UROY Comparison

Compare RIGL & UROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • UROY
  • Stock Information
  • Founded
  • RIGL 1996
  • UROY 2017
  • Country
  • RIGL United States
  • UROY Canada
  • Employees
  • RIGL N/A
  • UROY N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • UROY
  • Sector
  • RIGL Health Care
  • UROY
  • Exchange
  • RIGL Nasdaq
  • UROY Nasdaq
  • Market Cap
  • RIGL 335.5M
  • UROY 336.8M
  • IPO Year
  • RIGL 2000
  • UROY N/A
  • Fundamental
  • Price
  • RIGL $18.28
  • UROY $2.35
  • Analyst Decision
  • RIGL Buy
  • UROY Strong Buy
  • Analyst Count
  • RIGL 5
  • UROY 2
  • Target Price
  • RIGL $36.40
  • UROY $4.00
  • AVG Volume (30 Days)
  • RIGL 170.2K
  • UROY 4.6M
  • Earning Date
  • RIGL 08-05-2025
  • UROY 07-23-2025
  • Dividend Yield
  • RIGL N/A
  • UROY N/A
  • EPS Growth
  • RIGL N/A
  • UROY N/A
  • EPS
  • RIGL 2.08
  • UROY N/A
  • Revenue
  • RIGL $203,077,000.00
  • UROY $15,984,827.00
  • Revenue This Year
  • RIGL $14.41
  • UROY N/A
  • Revenue Next Year
  • RIGL $15.97
  • UROY N/A
  • P/E Ratio
  • RIGL $8.92
  • UROY N/A
  • Revenue Growth
  • RIGL 70.16
  • UROY N/A
  • 52 Week Low
  • RIGL $7.48
  • UROY $1.43
  • 52 Week High
  • RIGL $29.82
  • UROY $3.12
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 37.91
  • UROY 55.55
  • Support Level
  • RIGL $18.35
  • UROY $2.30
  • Resistance Level
  • RIGL $19.21
  • UROY $2.54
  • Average True Range (ATR)
  • RIGL 0.89
  • UROY 0.12
  • MACD
  • RIGL -0.33
  • UROY -0.01
  • Stochastic Oscillator
  • RIGL 2.15
  • UROY 37.18

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About UROY Uranium Royalty Corp.

Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.

Share on Social Networks: